Important Content Reminder:
-
Investment Types: (1) Idle raised funds will be used to purchase high liquidity and safety principal-protected investment products, such as large certificates of deposit and structured deposits issued by banks and financial institutions, with individual product investment periods not exceeding 12 months. (2) Self-owned funds will be invested in high safety and liquidity investment products, with channels including but not limited to commercial banks and securities companies.
-
Investment Amount: The company and its subsidiaries will use a total of no more than 300 million RMB (inclusive) of idle raised funds and no more than 200 million RMB (inclusive) of idle self-owned funds for cash management, ensuring that it does not affect the construction of investment projects and normal operations.
-
Special Risk Warning: Despite choosing high liquidity and safety investment products, there are still risks associated with macroeconomic fluctuations and potential underperformance of investment returns. Investors are advised to be aware of investment risks.
Guangdong Tai'enkang Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company" or "Tai'enkang") held the 15th meeting of the 5th Board of Directors on April 15, 2026, where it reviewed and approved the proposal on the use of temporarily idle raised funds and self-owned funds for cash management. The company and its subsidiaries are authorized to use a total of no more than 300 million RMB (inclusive) of idle raised funds and no more than 200 million RMB (inclusive) of idle self-owned funds for cash management, provided that it does not affect the construction of investment projects (hereinafter referred to as "Investment Projects") and normal operations. The cash management limit will be shared by the company and its subsidiaries, and the usage period is valid for 12 months from the date of board approval. The company and all board members guarantee the authenticity, accuracy, and completeness of the announcement content, with no false records, misleading statements, or significant omissions.
The funds can be used in a rolling manner, with the transaction amount at any point in time during the period (including related amounts reinvested from the investment returns) not exceeding the above limits. The specific situation is announced as follows:
1. Basic Situation of Raised Funds
According to the approval from the China Securities Regulatory Commission (hereinafter referred to as "CSRC") regarding the initial public offering of Guangdong Tai'enkang Pharmaceutical Co., Ltd. (CSRC Approval [2022] No. 203), the company issued 59.1 million shares of RMB ordinary shares (A shares) with a par value of 1.00 RMB per share at an issue price of 19.93 RMB/share, raising a total of 1,177.863 million RMB. After deducting related issuance costs (excluding tax) of 125.7823 million RMB, the actual net raised funds amounted to 1,052.0807 million RMB. The raised funds were transferred to the company's designated account on March 24, 2022. Huaxing Accounting Firm (Special General Partnership) verified the funds' arrival on March 24, 2022, and issued the "Verification Report No. Huaxing [2022] 20000260380."
2. Investment Projects of Raised Funds
According to the company's prospectus for the initial public offering and listing on the Growth Enterprise Market, the net raised funds after deducting issuance costs will be invested in the following projects: